Generic Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Date : Mar 2018

Formats :
Report Code : PMR83649626

Category : Pharmaceutical and Healthcare
No Of Pages :
Generic Drugs market: A generic drug is pharmaceutical drug, which is bio equivalent to branded drug. Generic drugs are usually approved after patent expiration of patent drugs.



Global Market Outline: Generic Drugs Market


Global generic drugs market is driven by the prevalence of various diseases, need for cost effective drugs for treatment, and government initiatives to increase the use of generic drugs. In addition, favourable regulatory policies, expiry of the branded drugs, and growth in biosimilars segment are expected to boost the generics drugs market. Furthermore, participants in the supply chain such as wholesalers, retailers and pharmacies also benefit from the sale of the generic drugs with high margins compared to branded generics. This emerged as key driver for the growth of global generic drugs market. However, lack of awareness about the availability of generic drugs, competition from branded generics and lack of price control are hampering the generic drugs market.



Generic Drugs market segmented based on therapeutic area and distribution channel



Based on therapeutic area, global generic drugs market is segmented into

Cardiovascular
CNS
Antibiotics
Oncology
Gastrointestinal
Hormones
Pain Management
Others
Based on distribution channel, global generic drugs market is segmented into

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others


Generic drugs market is highly fragmented market, presence of large players and small players. To improve their market position in generic drug market companies are adopting strategies like expanding their market presence through collaboration and entering into new markets. For instance, in January 2018, Medical inhaler company Vectura Group PLC collaborated with Sandoz, a division of Novartis AG, to develop a generic version of an inhaler therapy for asthma and COPD chronic obstructive pulmonary disease. In January 2017, Momenta collaborated with Mylan Laboratories for the development, manufacture and commercialization of six of its biosimilar candidates, including M834, Orencia abatacept a biosimilar candidate. Mergers and acquisitions are key strategies adopted by various market players. For instance, in August 2017, Teva Pharmaceutical Industries Ltd Acquired Allergen’s generic business Actavis Generics to expand their product, R&D portfolio and geographical footprint in generic market.



Geographically generic drugs market segmented into following regions viz. North America, Europe, AsiaPacific, Latin America, and Middle East & Africa. North America generic drugs market is expected to grow at significant rates owing to availability of more number of generics, increase awareness about the generic drugs and favourable regulatory policies and acts such as Affordable Care Act 2010. In Europe region, Belgium and UK expected to grow at notable rates owing to prevalence of chronic diseases, increase in investment on biosimilars, and increase awareness about generic drugs. Asia Pacific Region expected to be fastest growing due to increased government initiatives in usage of generic drugs and increase in awareness about generic drugs. Especially emerging countries like India government initiating different policies and schemes to boost the usage of generic drugs, For instance, Government of India taken an initiative of opening Jan aushadhi stores to make available quality generic medicines at affordable prices to all citizens.



Some of the market players in generic drugs market are Mylan N.V. U.S., Sun Pharmaceutical Industries Limited India, Teva Pharmaceutical Industries, Ltd. Israel, Dr Reddy’s Laboratories India, Novartis AG Sandoz International GmbH Switzerland, Apotex Holdings Inc. Canada, Endo International plc U.S., Pfizer Inc. U.S., Johnson & Johnson Services Inc., Janssen Pharmaceutica U.S., Lupin Limited India, Merck & Co, Inc. U.S., Mitsubishi Tanabe Pharma Japan, Momenta Pharmaceuticals U.S., Nexus Pharmaceuticals U.S., and Novo Nordisk Denmark to name a few.



In August 2018, Nexus Pharmaceuticals got U.S. FDA approval for the first generic version of Hospira’s Isuprel, for the treatment of bradycardia, heart block.
In January 2015, Ivax Pharmaceuticals, a subsidiary of Teva Pharmaceuticals has got FDA approval for first generic version of AstraZeneca’s Nexium to treat gastroesophageal reflux disease GERD.
1. Executive Summary
2. Global Generic Drugs Market Introduction
2.1. Global Generic Drugs Market – Taxonomy
2.2. Global Generic Drugs Market –Definitions
2.2.1. Therapeutic Area
2.2.2. Distribution Channel
3. Global Generic Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Generic Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Generic Drugs Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
3.7. Global Generic Drugs Market – Therapeutic Area Pipeline Analysis
4. Global Generic Drugs Market Analysis, 2013 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
4.2. YearoverYear YoY Growth Analysis %
4.3. Market Oppurtunity Analysis
5. Global Generic Drugs Market, By Therapeutic Area, 2013 2017 and Forecast, 2018 2024
5.1. Cardiovascular
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. CNS
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
5.3. Antibiotics
5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.3.3. Market Opportunity Analysis
5.4. Oncology
5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.4.3. Market Opportunity Analysis
5.5. Gastrointestinal
5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.5.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.5.3. Market Opportunity Analysis
5.6. Hormones
5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.6.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.6.3. Market Opportunity Analysis
5.7. Pain Management
5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.7.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.7.3. Market Opportunity Analysis
5.8. Others
5.8.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.8.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.8.3. Market Opportunity Analysis
6. Global Generic Drugs Market Forecast, By Distribution Channel, 2013 2017 and Forecast, 2018 2024
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.4.3. Market Opportunity Analysis
7. Global Generic Drugs Market Forecast, By Region, 2013 2017 and Forecast, 2018 2024
7.1. North America
7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. AsiaPacific
7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.5.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.5.3. Market Opportunity Analysis
7.6. Global Generic Drugs Market Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Region, 2018 – 2024
8. North America Generic Drugs Market Analysis, 2013 2017 and Forecast, 2018 2024
8.1. Therapeutic Area Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
8.1.1. Cardiovascular
8.1.2. CNS
8.1.3. Antibiotics
8.1.4. Oncology
8.1.5. Gastrointestinal
8.1.6. Hormones
8.1.7. Pain Management
8.1.8. Others
8.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.2.4. Others
8.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
8.3.1. U.S.
8.3.2. Canada
8.4. North America Generic Drugs Market Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Country, 2018 – 2024
8.5. North America Generic Drugs Market Dynamics – Trends
9. Europe Generic Drugs Market Analysis, 2013 2017 and Forecast, 2018 2024
9.1. Therapeutic Area Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.1.1. Cardiovascular
9.1.2. CNS
9.1.3. Antibiotics
9.1.4. Oncology
9.1.5. Gastrointestinal
9.1.6. Hormones
9.1.7. Pain Management
9.1.8. Others
9.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
9.2.4. Others
9.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Poland
9.3.8. Rest of Europe
9.4. Europe Generic Drugs Market Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Country, 2018 – 2024
9.5. Europe Generic Drugs Market Dynamics – Trends
10. AsiaPacific Generic Drugs Market Analysis, 2013 2017 and Forecast, 2018 2024
10.1. Therapeutic Area Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.1.1. Cardiovascular
10.1.2. CNS
10.1.3. Antibiotics
10.1.4. Oncology
10.1.5. Gastrointestinal
10.1.6. Hormones
10.1.7. Pain Management
10.1.8. Others
10.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
10.2.1. Hospital Pharmacies
10.2.2. Retail Pharmacies
10.2.3. Online Pharmacies
10.2.4. Others
10.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn,
YoY Growth %, and Market Share %
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of AsiaPacific
10.4. AsiaPacific Generic Drugs Market Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Country, 2018 – 2024
10.5. AsiaPacific Generic Drugs Market Dynamics – Trends
11. Latin America Generic Drugs Market Analysis, 2013 2017 and Forecast, 2018 2024
11.1. Therapeutic Area Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.1.1. Cardiovascular
11.1.2. CNS
11.1.3. Antibiotics
11.1.4. Oncology
11.1.5. Gastrointestinal
11.1.6. Hormones
11.1.7. Pain Management
11.1.8. Others
11.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
11.2.1. Hospital Pharmacies
11.2.2. Retail Pharmacies
11.2.3. Online Pharmacies
11.2.4. Others
11.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Venezuela
11.3.5. Rest of Latin America
11.4. Latin America Generic Drugs Market Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Country, 2018 – 2024
11.5. Latin America Generic Drugs Market Dynamics – Trends
12. Middle East and Africa Generic Drugs Market Analysis, 2013 2017 and Forecast, 2018 2024
12.1. Therapeutic Area Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.1.1. Cardiovascular
12.1.2. CNS
12.1.3. Antibiotics
12.1.4. Oncology
12.1.5. Gastrointestinal
12.1.6. Hormones
12.1.7. Pain Management
12.1.8. Others
12.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
12.2.1. Hospital Pharmacies
12.2.2. Retail Pharmacies
12.2.3. Online Pharmacies
12.2.4. Others
12.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.3.1. Gulf Cooperation Council GCC Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Generic Drugs Market Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Country, 2018 – 2024
12.5. MEA Generic Drugs Market Dynamics – Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles Introduction, Financial Analysis, Therapeutic Area & Service Offerings, Key Developments, Strategies, and SWOT Analysis
13.2.1. Mylan N.V. U.S.
13.2.2. Sun Pharmaceutical Industries Limited India
13.2.3. Teva Pharmaceutical Industries, Ltd. Israel
13.2.4. Dr Reddy’s Laboratories India
13.2.5. Novartis AG Sandoz International GmbH Switzerland
13.2.6. Apotex Holdings Inc. Canada
13.2.7. Endo International plc U.S.
13.2.8. Pfizer Inc. U.S.
13.2.9. Johnson & Johnson Services Inc., Janssen Pharmaceutica U.S.
13.2.10. Lupin Limited India
13.2.11. Merck & Co, Inc. U.S.
13.2.12. Mitsubishi Tanabe Pharma Japan
13.2.13. Momenta Pharmaceuticals U.S.
13.2.14. Nexus Pharmaceuticals U.S.
13.2.15. Novo Nordisk Denmark
14. Research Methodology
15. Key Assumptions and Acronyms
  Purchase Options for Report

Need More information

Call us :
USA : +1 7162260907
UK : +44 7441952057
....
sales@planetmarketreports.com

Why to PMR

PMR Market Research

Our syndicated research reports cover 50+ industry sectors offering you product and country wise breakup of the market along with niche data and insights that will help you make informed business decision. Our research is focused on the key segments of an industry that possess opportunities of growth.

  • Industrial ...
  • Business ....
  • Consumer ....
  • Peer ....